Literature DB >> 24142190

Validation of a Quality of Life Questionnaire for Bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0.

Casilda Olveira1, Gabriel Olveira, Francisco Espildora, Rosa-Maria Giron, Gerard Muñoz, Alexandra L Quittner, Miguel-Angel Martinez-Garcia.   

Abstract

PURPOSE: Bronchiectasis is a chronic disease, leading to worsening of health-related quality of life. This study evaluated the psychometric properties of a new patient-reported outcome for non-cystic fibrosis bronchiectasis, the Quality of Life Questionnaire Bronchiectasis, translated into Spanish (QOL-B-Sp-V3.0).
METHODS: This prospective study recruited clinically stable patients with non-cystic fibrosis bronchiectasis at 4 Spanish centers. Health status was assessed with multiple indicators (dyspnea, exacerbations, bronchorrhea, etc.), microbiological, radiological, spirometric, and anthropometric parameters plus St-George Respiratory Questionnaire (SGRQ). Psychometric analyses included internal consistency, test-retest reliability, convergent validity, predictive validity, and responsivity to change.
RESULTS: The 207 stable patients (mean age 57.2 years) had a Bhalla score of 11.53 ± 7.39 and FEV1% of 68.3 ± 22.2 %. One hundred and sixty-one stable patients repeated the test 2 weeks later, and 80 patients who had an exacerbation within 6 months of the assessment also repeated it. Internal consistency was high across all scales (Cronbach's alpha >0.70). Thirty-six of 37 items correlated more strongly with their assigned scale than a competing scale. Test-retest coefficients were strong (intraclass correlations r = 0.68-0.88). All scales, except Treatment Burden, discriminated significantly between patients with mild, moderate, and severe disease according to FEV1% and other respiratory parameters. Strong convergence was found between the QOL-B-Sp-V3.0 and SGRQ. Significant correlations were found between QOL-B-Sp-V3.0 and various clinical, spirometric, radiological, and anthropometric variables. Significant differences were found on all QOL-B-Sp-V3.0 scales, except emotional functioning, between the baseline responses and onset of an exacerbation; robust sensitivity to change was observed on the Respiratory Symptoms scale.
CONCLUSIONS: The QOL-B-Sp-V3.0 questionnaire demonstrated strong reliability and validity. Scores were reproducible after 2 weeks, and it discriminated between patients who varied in severity and was responsive to changes related to exacerbation.

Entities:  

Mesh:

Year:  2013        PMID: 24142190     DOI: 10.1007/s11136-013-0560-0

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  24 in total

Review 1.  British Thoracic Society guideline for non-CF bronchiectasis.

Authors:  M C Pasteur; D Bilton; A T Hill
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

2.  Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.

Authors:  M P Murray; K Turnbull; S MacQuarrie; J L Pentland; A T Hill
Journal:  Eur Respir J       Date:  2009-02-05       Impact factor: 16.671

Review 3.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

Authors:  B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-04       Impact factor: 4.406

4.  Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis.

Authors:  Shelley L Chan; Moira M Chan-Yeung; Gaik C Ooi; Cindy L Lam; Tung F Cheung; Wah K Lam; Kenneth W Tsang
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

5.  Spirometric reference values from a Mediterranean population.

Authors:  J Roca; J Sanchis; A Agusti-Vidal; F Segarra; D Navajas; R Rodriguez-Roisin; P Casan; S Sans
Journal:  Bull Eur Physiopathol Respir       Date:  1986 May-Jun

6.  Computed tomography of bronchiectasis.

Authors:  D P Naidich; D I McCauley; N F Khouri; F P Stitik; S S Siegelman
Journal:  J Comput Assist Tomogr       Date:  1982-06       Impact factor: 1.826

7.  Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis.

Authors:  Miguel Ángel Martínez-García; Juan J Soler-Cataluña; Pablo Catalán-Serra; Pilar Román-Sánchez; Miguel Perpiñá Tordera
Journal:  Chest       Date:  2011-07-21       Impact factor: 9.410

8.  Relationship between psychological well-being and lung health status in patients with bronchiectasis.

Authors:  C J O'Leary; C B Wilson; D M Hansell; P J Cole; R Wilson; P W Jones
Journal:  Respir Med       Date:  2002-09       Impact factor: 3.415

9.  Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

Authors:  George Z Retsch-Bogart; Alexandra L Quittner; Ronald L Gibson; Christopher M Oermann; Karen S McCoy; A Bruce Montgomery; Peter J Cooper
Journal:  Chest       Date:  2009-05       Impact factor: 9.410

10.  Fat-free mass depletion and inflammation in patients with bronchiectasis.

Authors:  Gabriel Olveira; Casilda Olveira; Inmaculada Gaspar; Nuria Porras; Gracia Martín-Núñez; Elehazara Rubio; Natalia Colomo; Gemma Rojo-Martínez; Federico Soriguer
Journal:  J Acad Nutr Diet       Date:  2012-12       Impact factor: 4.910

View more
  9 in total

1.  Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence.

Authors:  David de la Rosa; Miguel-Angel Martínez-Garcia; Casilda Olveira; Rosa Girón; Luis Máiz; Concepción Prados
Journal:  Chron Respir Dis       Date:  2016-07-07       Impact factor: 2.444

Review 2.  Measuring the burden of treatment for chronic disease: implications of a scoping review of the literature.

Authors:  Adem Sav; Asiyeh Salehi; Frances S Mair; Sara S McMillan
Journal:  BMC Med Res Methodol       Date:  2017-09-12       Impact factor: 4.615

Review 3.  Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review.

Authors:  Luis Máiz Carro; Miguel A Martínez-García
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

4.  In bronchiectasis, poor physical capacity correlates with poor quality of life.

Authors:  Jarkko Mäntylä; Witold Mazur; Tanja Törölä; Paula Bergman; Paula Kauppi
Journal:  Eur Clin Respir J       Date:  2022-06-30

5.  Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients.

Authors:  Luis Máiz; Rosa M Girón; Eva Prats; Marta G Clemente; Eva Polverino; Silvia Caño; Rosa Cordovilla; Jordi Dorca; Carlos Peñalver; Félix Baranda; Miguel A Martínez-García
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

Review 6.  Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics.

Authors:  Kate H Regan; Adam T Hill
Journal:  Curr Pulmonol Rep       Date:  2018-07-05

7.  Exacerbations and Changes in Physical Activity and Sedentary Behaviour in Patients with Bronchiectasis after 1 Year.

Authors:  Victoria Alcaraz-Serrano; Ane Arbillaga-Etxarri; Patricia Oscanoa; Laia Fernández-Barat; Leticia Bueno; Rosanel Amaro; Elena Gimeno-Santos; Antoni Torres
Journal:  J Clin Med       Date:  2021-03-12       Impact factor: 4.241

8.  Psychometric Validation of the German Translation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B)-Data from the German Bronchiectasis Registry PROGNOSIS.

Authors:  Laura Quellhorst; Grit Barten-Neiner; Andrés de Roux; Roland Diel; Pontus Mertsch; Isabell Pink; Jessica Rademacher; Sivagurunathan Sutharsan; Tobias Welte; Annegret Zurawski; Felix C Ringshausen
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

9.  The Predictive Role of Psychological Status and Disease Severity Indexes on Quality of Life Among Patients with Non-CF Bronchiectasis.

Authors:  Berrin Ceyhan; Melahat Bekir; Derya Kocakaya; Sehnaz Olgun Yildizeli; Semiha Emel Eryuksel
Journal:  Turk Thorac J       Date:  2022-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.